AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

TEPKINLY® (epcoritamab) combined with lenalidomide and rituximab (R2) has received European approval as the first and only bispecific-based therapy for relapsed/refractory follicular lymphoma in the second-line setting, providing a chemotherapy-free option. The approval is based on results from the Phase 3 EPCORE® FL-1 trial, positioning the regimen as a new standard option for this patient segment.

Analysis

TEPKINLY® (epcoritamab) combined with lenalidomide and rituximab (R2) has received European approval as the first and only bispecific-based therapy for relapsed/refractory follicular lymphoma in the second-line setting, providing a chemotherapy-free option. The approval is based on results from the Phase 3 EPCORE® FL-1 trial, positioning the regimen as a new standard option for this patient segment.